For cell reprogramming, context matters

Differentiated cells in a culture dish can assume a new identity when manipulated to express four transcription factors. This “reprogramming” process has sparked interest because conceivably it could be harnessed as a therapeutic strategy for tissue regeneration. Mosteiro et al. used a mouse model to study the signals that promote cell reprogramming in vivo. They found that the factors that trigger reprogramming in vitro do the same in vivo; however, they also inflict cell damage. The damaged cells enter a state of senescence and begin secreting certain factors that promote reprogramming, including an inflammatory cytokine called interleukin-6. Thus, in the physiological setting, cell senescence may create a tissue context that favors reprogramming of neighboring cells.
Science, this issue p. 10.1126/science.aaf4445

Structured Abstract


The ectopic expression of transcription factors OCT4, SOX2, KLF4, and cMYC (OSKM) enables reprogramming of adult differentiated cells into pluripotent cells, known as induced pluripotent stem cells (iPSCs), that are functionally equivalent to embryonic stem cells. Expression of OSKM in vivo leads to widespread cell dedifferentiation and reprogramming within tissues and eventually to the formation of teratomas (tumors arising from iPSCs). The molecular mechanisms operating during in vitro OSKM-driven reprogramming have been extensively characterized; however, little is known about in vivo reprogramming.


The process of OSKM reprogramming is inefficient both in vitro and in vivo. A number of cell-intrinsic barriers have been identified in vitro, most of which are activated by cellular damage and are particularly prominent in aged cells. Mechanistically, these cell-intrinsic barriers for reprogramming are primarily mediated by the tumor suppressors p53, p16INK4a, and ARF (the latter two are encoded by the Ink4a/Arf gene locus). In this work, we have investigated the effect of these tumor suppressors, cellular damage, and aging on in vivo reprogramming.


We found that the expression of OSKM in vivo not only triggers reprogramming of some cells but also inflicts extensive damage on many other cells, driving them into a state known as cellular senescence. Senescent cells are characterized by their inability to proliferate and by their secretion of inflammatory cytokines. We have observed a positive correlation between senescence and OSKM-driven reprogramming. For example, tissues lacking p16INK4a/ARF do not undergo senescence, and their ability to reprogram is severely compromised. By contrast, in tissues lacking p53, damage is rampant; this leads to maximal levels of senescence, exacerbated cytokine production, and increased in vivo reprogramming.
To explore the connection between senescence and reprogramming, we manipulated these processes in vivo through pharmacological interventions. In particular, an increase in senescence produced by palbociclib (a drug that functionally mimics p16INK4a) results in higher levels of reprogramming. Conversely, a reduction in senescence achieved by navitoclax (a proapoptotic drug with selectivity against senescent cells) leads to decreased in vivo reprogramming. We found that the cross-talk between senescence and reprogramming is mediated by the cytokine-rich microenvironment associated with senescent cells. This is based, among other evidence, on the observation that pharmacological inhibition of NFκB, a major driver of cytokine production, reduces in vivo reprogramming. Analysis of the inflammatory cytokines produced by senescent cells, both in vivo and in vitro, led us to identify interleukin-6 (IL-6) as a critical secreted factor responsible for the ability of senescent cells to promote reprogramming. In support of this, blockade of IL-6 or its downstream kinase effector PIM potently reduced in vivo reprogramming. These observations can be recapitulated in vitro, where reprogramming efficiency is strongly enhanced by the presence of damaged cells or by the conditioned medium derived from damaged cells. Moreover, immunodepletion of IL-6 from the conditioned medium abolished reprogramming.
Having established that senescence promotes reprogramming, we studied whether tissue injury leading to senescence has a positive effect on OSKM-driven reprogramming. In particular, we show that bleomycin-induced tissue damage strongly promotes reprogramming in the lung. Finally, aging, which is associated with higher levels of cellular senescence, also favors OSKM-driven reprogramming both in progeric and in physiologically aged mice.


The expression of OSKM in vivo triggers two different cellular outcomes: reprogramming in a small fraction of cells, and damage and senescence in many other cells. There is a strong positive association between these two processes, due to the fact that cellular senescence creates a tissue context that favors OSKM-driven reprogramming in neighboring cells. The positive effect of senescence on reprogramming is mediated by secreted factors, of which IL-6 is a key player. This also applies to tissue injury and aging, where there is an accumulation of senescent cells that send signals to surrounding cells to promote OSKM-driven dedifferentiation and reprogramming. A similar conceptual interplay may occur in physiological conditions, where damage-triggered senescence could induce cell dedifferentiation to promote tissue repair.
Interplay between cellular senescence and OSKM-driven reprogramming.
Expression of OSKM in vivo, apart from inducing the reprogramming of a small population of cells, also induces damage and senescence in many other cells. Senescent cells release factors that promote the reprogramming of neighboring cells, with IL-6 being a critical mediator. Tissue injury and aging, through the accumulation of senescent cells, favor in vivo reprogramming.


Reprogramming of differentiated cells into pluripotent cells can occur in vivo, but the mechanisms involved remain to be elucidated. Senescence is a cellular response to damage, characterized by abundant production of cytokines and other secreted factors that, together with the recruitment of inflammatory cells, result in tissue remodeling. Here, we show that in vivo expression of the reprogramming factors OCT4, SOX2, KLF4, and cMYC (OSKM) in mice leads to senescence and reprogramming, both coexisting in close proximity. Genetic and pharmacological analyses indicate that OSKM-induced senescence requires the Ink4a/Arf locus and, through the production of the cytokine interleukin-6, creates a permissive tissue environment for in vivo reprogramming. Biological conditions linked to senescence, such as tissue injury or aging, favor in vivo reprogramming by OSKM. These observations may be relevant for tissue repair.

Get full access to this article

View all available purchase options and get full access to this article.

Already a subscriber or AAAS Member? Log In

Supplementary Material


Supplementary Text
Figs. S1 to S6
Reference (46)


File (


Robinton D. A., Daley G. Q., The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295–305 (2012).
Takahashi K., Yamanaka S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
Abad M., Mosteiro L., Pantoja C., Cañamero M., Rayon T., Ors I., Graña O., Megías D., Domínguez O., Martínez D., Manzanares M., Ortega S., Serrano M., Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 502, 340–345 (2013).
Ohnishi K., Semi K., Yamamoto T., Shimizu M., Tanaka A., Mitsunaga K., Okita K., Osafune K., Arioka Y., Maeda T., Soejima H., Moriwaki H., Yamanaka S., Woltjen K., Yamada Y., Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 156, 663–677 (2014).
Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., Zhang Q., Xiang C., Hou P., Song Z., Liu Y., Yong J., Zhang P., Cai J., Liu M., Li H., Li Y., Qu X., Cui K., Zhang W., Xiang T., Wu Y., Zhao Y., Liu C., Yu C., Yuan K., Lou J., Ding M., Deng H., Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3, 475–479 (2008).
Banito A., Rashid S. T., Acosta J. C., Li S., Pereira C. F., Geti I., Pinho S., Silva J. C., Azuara V., Walsh M., Vallier L., Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 23, 2134–2139 (2009).
Li H., Collado M., Villasante A., Strati K., Ortega S., Cañamero M., Blasco M. A., Serrano M., The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136–1139 (2009).
Marión R. M., Strati K., Li H., Murga M., Blanco R., Ortega S., Fernandez-Capetillo O., Serrano M., Blasco M. A., A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149–1153 (2009).
Kawamura T., Suzuki J., Wang Y. V., Menendez S., Morera L. B., Raya A., Wahl G. M., Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460, 1140–1144 (2009).
Utikal J., Polo J. M., Stadtfeld M., Maherali N., Kulalert W., Walsh R. M., Khalil A., Rheinwald J. G., Hochedlinger K., Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145–1148 (2009).
Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., Okita K., Yamanaka S., Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature 460, 1132–1135 (2009).
Freund A., Orjalo A. V., Desprez P.-Y., Campisi J., Inflammatory networks during cellular senescence: Causes and consequences. Trends Mol. Med. 16, 238–246 (2010).
Salama R., Sadaie M., Hoare M., Narita M., Cellular senescence and its effector programs. Genes Dev. 28, 99–114 (2014).
Coppé J.-P., Patil C. K., Rodier F., Sun Y., Muñoz D. P., Goldstein J., Nelson P. S., Desprez P.-Y., Campisi J., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLOS Biol. 6, 2853–2868 (2008).
Kuilman T., Michaloglou C., Vredeveld L. C.W., Douma S., van Doorn R., Desmet C. J., Aarden L. A., Mooi W. J., Peeper D. S., Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).
Acosta J. C., O’Loghlen A., Banito A., Guijarro M. V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., Takatsu Y., Melamed J., d’Adda di Fagagna F., Bernard D., Hernando E., Gil J., Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
López-Otín C., Blasco M. A., Partridge L., Serrano M., Kroemer G., The hallmarks of aging. Cell 153, 1194–1217 (2013).
Muñoz-Espin D., Serrano M., Cellular senescence: From physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
Chang J., Wang Y., Shao L., Laberge R.-M., Demaria M., Campisi J., Janakiraman K., Sharpless N. E., Ding S., Feng W., Luo Y., Wang X., Aykin-Burns N., Krager K., Ponnappan U., Hauer-Jensen M., Meng A., Zhou D., Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016).
Zhu Y., Tchkonia T., Fuhrmann-Stroissnigg H., Dai H. M., Ling Y. Y., Stout M. B., Pirtskhalava T., Giorgadze N., Johnson K. O., Giles C. B., Wren J. D., Niedernhofer L. J., Robbins P. D., Kirkland J. L., Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2015).
Yosef R., Pilpel N., Tokarsky-Amiel R., Biran A., Ovadya Y., Cohen S., Vadai E., Dassa L., Shahar E., Condiotti R., Ben-Porath I., Krizhanovsky V., Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).
Dickson M. A., Molecular pathways: CDK4 inhibitors for cancer therapy. Clin. Cancer Res. 20, 3379–3383 (2014).
Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J. E., Premsrirut P., Luo W., Chicas A., Lee C. S., Kogan S. C., Lowe S. W., Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125–2136 (2011).
Freund A., Patil C. K., Campisi J., p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536–1548 (2011).
Gasparian A. V., Guryanova O. A., Chebotaev D. V., Shishkin A. A., Yemelyanov A. Y., Budunova I. V., Targeting transcription factor NFκB: Comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8, 1559–1566 (2009).
Acosta J. C., Banito A., Wuestefeld T., Georgilis A., Janich P., Morton J. P., Athineos D., Kang T.-W., Lasitschka F., Andrulis M., Pascual G., Morris K. J., Khan S., Jin H., Dharmalingam G., Snijders A. P., Carroll T., Capper D., Pritchard C., Inman G. J., Longerich T., Sansom O. J., Benitah S. A., Zender L., Gil J., A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990 (2013).
Brady J. J., Li M., Suthram S., Jiang H., Wong W. H., Blau H. M., Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat. Cell Biol. 15, 1244–1252 (2013).
Narlik-Grassow M., Blanco-Aparicio C., Carnero A., The PIM family of serine/threonine kinases in cancer. Med. Res. Rev. 34, 136–159 (2014).
Kim K., Kim J. H., Youn B. U., Jin H. M., Kim N., Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction. J. Immunol. 185, 7460–7466 (2010).
Nihira K., Ando Y., Yamaguchi T., Kagami Y., Miki Y., Yoshida K., Pim-1 controls NF-κB signalling by stabilizing RelA/p65. Cell Death Differ. 17, 689–698 (2010).
Aoshiba K., Tsuji T., Nagai A., Bleomycin induces cellular senescence in alveolar epithelial cells. Eur. Respir. J. 22, 436–443 (2003).
Aoshiba K., Tsuji T., Kameyama S., Itoh M., Semba S., Yamaguchi K., Nakamur H., Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp. Toxicol. Pathol. 65, 1053–1062 (2013).
Blasco M. A., Lee H.-W., Hande M. P., Samper E., Lansdorp P. M., DePinho R. A., Greider C. W., Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25–34 (1997).
García-Cao I., García-Cao M., Tomás-Loba A., Martin-Caballero J., Flores J. M., Klatt P., Blasco M. A., Serrano M., Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep. 7, 546–552 (2006).
Krishnamurthy J., Torrice C., Ramsey M. R., Kovalev G. I., Al-Regaiey K., Su L., Sharpless N. E., Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299–1307 (2004).
Soria-Valles C., López-Otín C., iPSCs: On the road to reprogramming aging. Trends Mol. Med. 22, 713–724 (2016).
Jessen K. R., Mirsky R., Arthur-Farraj P., The role of cell plasticity in tissue repair: Adaptive cellular reprogramming. Dev. Cell 34, 613–620 (2015).
Jacks T., Remington L., Williams B. O., Schmitt E. M., Halachmi S., Bronson R. T., Weinberg R. A., Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994).
Serrano M., Lee H.-W., Chin L., Cordon-Cardo C., Beach D., DePinho R. A., Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).
Fu X., The immunogenicity of cells derived from induced pluripotent stem cells. Cell. Mol. Immunol. 11, 14–16 (2014).
Dickins R. A., Hemann M. T., Zilfou J. T., Simpson D. R., Ibarra I., Hannon G. J., Lowe S. W., Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289–1295 (2005).
Trapnell C., Roberts A., Goff L., Pertea G., Kim D., Kelley D. R., Pimentel H., Salzberg S. L., Rinn J. L., Pachter L., Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).
Langmead B., Trapnell C., Pop M., Salzberg S. L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R., The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550 (2005).
Pastor J., Oyarzabal J., Saluste G., Alvarez R. M., Rivero V., Ramos F., Cendón E., Blanco-Aparicio C., Ajenjo N., Cebriá A., Albarrán M. I., Cebrián D., Corrionero A., Fominaya J., Montoya G., Mazzorana M., Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. Bioorg. Med. Chem. Lett. 22, 1591–1597 (2012).

Information & Authors


Published In

Volume 354 | Issue 6315
25 November 2016

Submission history

Received: 9 February 2016
Accepted: 6 October 2016
Published in print: 25 November 2016


Request permissions for this article.


We are grateful to R. Serrano, L. Martínez, O. Domínguez, P. González, M. Gómez, M. Udriste, Z. Vega, M. Lozano, and G. Hernández for technical support. L.M. was a recipient of an FPU contract from the Spanish Ministry of Education (MECD). N.A. was a recipient of an FPI contract from the Spanish Ministry of Economy (MINECO). D.C. and M.R. were recipients of a fellowship from La Caixa. P.J.F.-M. was funded by the Spanish Association Against Cancer (AECC). Work in the laboratory of M.S. is funded by the CNIO and by grants from the MECD cofunded by the European Regional Development Fund (SAF project), the European Research Council (ERC Advanced Grant), the Regional Government of Madrid cofunded by the European Social Fund (ReCaRe project), the European Union (RISK-IR project), the Botín Foundation and Banco Santander (Santander Universities Global Division), the Ramón Areces Foundation, and the AXA Foundation. Work in the laboratory of M.A.B. is funded by the CNIO, MINECO, ERC Advanced Grant, the European Union, the Botin Foundation, and Banco Santander, WRC, and the AXA Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. M.S. is a paid adviser for UNITY Biotechnology Inc., a company developing senolytic medicines.



Lluc Mosteiro
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Cristina Pantoja*
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Noelia Alcazar*
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Rosa M. Marión
Telomeres and Telomerase Group, CNIO, Madrid E28029, Spain.
Dafni Chondronasiou
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Miguel Rovira
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Pablo J. Fernandez-Marcos
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Laboratory of Bioactive Products and Metabolic Syndrome, Madrid Institute for Advanced Studies (IMDEA) in Food, CEI UAM+CSIC, Madrid E28049, Spain.
Maribel Muñoz-Martin
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Carmen Blanco-Aparicio
Experimental Therapeutics Programme, CNIO, Madrid E28029, Spain.
Joaquin Pastor
Experimental Therapeutics Programme, CNIO, Madrid E28029, Spain.
Gonzalo Gómez-López
Bioinformatics Unit, CNIO, Madrid E28029, Spain.
Alba De Martino
Histopathology Unit, CNIO, Madrid E28029, Spain.
Maria A. Blasco
Telomeres and Telomerase Group, CNIO, Madrid E28029, Spain.
María Abad
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.
Cell Plasticity and Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona E08035, Spain.
Manuel Serrano [email protected]
Tumor Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid E28029, Spain.


These authors contributed equally to this work.
Corresponding author. Email: [email protected]

Metrics & Citations


Article Usage


Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. Characteristics of senescent cells, Regenerative Nephrology, (231-240), (2022).
  2. Senescence, immune microenvironment, and vascularization in cardiac myxomas, Cardiovascular Pathology, 52, (107335), (2021).
  3. Breathe it in – spotlight on senescence and regeneration in the lung, Mechanisms of Ageing and Development, (111550), (2021).
  4. Senescence under appraisal: hopes and challenges revisited, Cellular and Molecular Life Sciences, 78, 7, (3333-3354), (2021).
  5. Bone Aging, Cellular Senescence, and Osteoporosis, JBMR Plus, 5, 4, (2021).
  6. A ride through the epigenetic landscape: aging reversal by reprogramming, GeroScience, 43, 2, (463-485), (2021).
  7. The role of cellular senescence in tissue repair and regeneration, Mechanisms of Ageing and Development, 198, (111528), (2021).
  8. Dynamics of alternative splicing during somatic cell reprogramming reveals functions for RNA-binding proteins CPSF3, hnRNP UL1, and TIA1, Genome Biology, 22, 1, (2021).
  9. Cellular and molecular features of senescence in acute lung injury, Mechanisms of Ageing and Development, 193, (111410), (2021).
  10. Acid ceramidase promotes senescent cell survival, Aging, 13, 12, (15750-15769), (2021).
  11. See more

View Options

Check Access

Log in to view the full text


AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in via OpenAthens.
Log in via Shibboleth.
More options

Register for free to read this article

As a service to the community, this article is available for free. Login or register for free to read this article.

Purchase this issue in print

Buy a single issue of Science for just $15 USD.

View options

PDF format

Download this article as a PDF file

Download PDF







Share article link

Share on social media